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PDZK1 inhibits the development and progression of renal
cell carcinoma by suppression of SHP-1 phosphorylation
T Tao1,5, X Yang1,2,5, J Zheng1,2, D Feng3, Q Qin1,2, X Shi1, Q Wang1, C Zhao1, Z Peng1, H Liu1,2, WG Jiang4 and J He1,2
Renal cell carcinoma (RCC) is one of the most aggressive urologic cancers, however, the mechanism on supporting RCC
carcinogenesis is still not clear. By using gene expression proﬁle analysis and functional clustering, PDZ domain-containing 1 (PDZK1)
was revealed to be downregulated in human clear cell renal cell carcinoma (ccRCC) samples, which was also veriﬁed in several
independent public ccRCC data sets. Using PDZK1 overexpression and knockdown models in ccRCC cell lines, we demonstrated that
PDZK1 inhibited cell proliferation, cell cycle G1/S phase transition, cell migration and invasion, indicating a tumor-suppressor role in
the development and progression of ccRCC. Our study further demonstrated that PDZK1 inhibited cell proliferation and migration of
ccRCC via targeting SHP-1. PDZK1 was further identiﬁed to suppress cell proliferation by blocking SHP-1 phosphorylation at Tyr536
via inhibition of the association between SHP-1 and PLCβ3, and then retarding Akt phosphorylation and promoting STAT5
phosphorylation in ccRCC cells. Moreover, the inhibitive effects of PDZK1 on SHP-1 phosphorylation and the tumor growth were
veriﬁed in vivo by xenograft tumor studies. Accordingly, PDZK1 expression was negatively correlated with SHP-1 activation and
phosphorylation, advanced pathologic stage, tumor weight and size, and prognosis of ccRCC patients. These ﬁndings have provided
ﬁrst lines of evidences that PDZK1 expression is negatively correlated with SHP-1 activation and poor clinical outcomes in ccRCC.
PDZK1 was identiﬁed as a novel tumor suppressor in ccRCC by negating SHP-1 activity.
Oncogene (2017) 36, 6119–6131; doi:10.1038/onc.2017.199; published online 10 July 2017
INTRODUCTION
Renal cell carcinoma (RCC) is an aggressive urologic cancer type.
Its incidence increases annually ~ 2%.1 Clear cell renal cell
carcinoma (ccRCC) accounts for 75% of all kidney tumors.2
Chemotherapy and radiotherapy are less-effective treatments
against ccRCC. Recent advances in molecular biology have
revealed that angiogenesis and tumor cell proliferation have
important roles for the development and progression of ccRCC.3,4
These ﬁndings provide a theoretical basis for ccRCC-targeted
therapies and have greatly changed the therapeutic landscape
in ccRCC.
It has been well known that inactivation of tumor-suppressor
VHL (Von Hippel-Lindau) results in an accumulation of hypoxia-
inducible factor (HIF), which contributes to neoangiogenesis in
480% ccRCC.5,6 Thus, at present, most RCC-targeted drugs are
mainly designed to inhibit angiogenic pathways,7 but have only
achieved a limited survival-time improvement.8 Traditionally, the
evaluation of the parameters of tumor cell proliferation including
tumor size, mitotic index, proliferation cell nuclear antigen and
Ki67 antigen have been suggested as having prognostic
importance in RCC.9 However, the molecular mechanisms on
the deregulation of cell proliferation in RCC is still largely
unknown. Uncovering these mechanisms may aid in the
clarity of the pathogenesis of RCC and advancement of more
effective therapy.
Recently, there has been an increasing interesting for the PDZ
domain-containing proteins, which have essential roles in tumor
growth, development and metastasis.10 Studies have established
that several PDZ proteins including TIP-1, DLG, Erbin and NHERF1
are involved in tumorigenesis such as colorectal and breast
cancers.11–14 The NHERF family of PDZ proteins are commonly
expressed in polarized epithelia.15 Abnormal expression of
NHERF1 has been found in several types of tumors, such as
hepatocellular carcinoma, breast cancer and nerve
schwannoma.14 NHERF1 expression is also related to cancer
invasion and metastasis.16 Over 150 PDZ proteins have been
found in the human proteome, and many of which are highly
expressed in renal epithelial cells.17 However, the roles of PDZ
proteins in renal cancer carcinogenesis and progression are largely
unknown.
In this study, differential gene expression analysis using the
available mRNA expression proﬁle of ccRCC from GEO data set
combined with GO analysis was used for the screening of target
PDZ proteins associated with cell proliferation. Among 2267
downregulated genes, PDZK1, a member of PDZ proteins, is
downregulated and associated with cell proliferation in ccRCC.
Loss of PDZK1 is demonstrated to be correlated with advanced
clinical stage and adverse prognosis in ccRCC. PDZK1 retarded cell
growth and promoted cell cycle arrest of ccRCC cells in vivo and
in vitro by blocking SHP-1 phosphorylation through suppression of
SHP-1 binding to PLCβ3. These data support a novel tumor-
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suppressor role of PDZK1 and provide a new insight into the
development and progression of ccRCC.
RESULTS
Low expression of PDZK1 predicts poor survival in ccRCC
To identify aberrantly expressed genes associated with ccRCC
carcinogenesis and progression, the mRNA expression proﬁle
obtained from GSE53757 (http://www.ncbi.nlm.nih.gov/geo/) with
72 paired ccRCC and adjacent non-tumor renal tissues were
analyzed. Totally, 2267 genes were signiﬁcantly downregulated in
ccRCC tissues by GEO2R analysis. DAVID (Database for Annotation,
Visualization and Integrated Discovery, developed by NIAID/NIH)
was then used to investigate gene ontology (GO) term enrich-
ment. GO analysis revealed that 40 genes, related to the biological
process of ‘cell proliferation’, and 10 genes associated with the
molecular function of ‘PDZ domain binding’, were downregulated
in ccRCC tissues. Only TGFBR3 and PDZK1 genes were associated
to both ‘cell proliferation’ and ‘PDZ domain binding’ (Po0.001;
Supplementary Figure S1). TGFBR3 has been involved in ccRCC
carcinogenesis.18 However, the role and relevance of PDZK1 in
ccRCC are still largely unknown, so we focused on exploring
physiological and pathological signiﬁcance of PDZK1 in this study.
To verify these ﬁndings, the expression of PDZK1 mRNA in
ccRCC and their adjacent tissues were analyzed either with GEO
ccRCC data set or TCGA’s RNA-seq data of ccRCC patients; all the
results showed that PDZK1 mRNA expression level was obviously
downregulated in ccRCC tissues as compared with adjacent non-
tumor renal tissues (Figures 1a and b). Further analysis of PDZK1
mRNA levels from ﬁve independent published studies in
ONCOMINE database entirely conﬁrmed our results that PDZK1
mRNA expression was signiﬁcantly lower in ccRCC tissues than
that in normal renal tissues (Figure 1c). Moreover, analysis of
PDZK1 protein expression in tissue microarray of 90 ccRCC
specimens also conﬁrmed that PDZK1 expression was reduced
in ccRCC tissues at protein level (Figures 1d and e).
To explore the clinical relevance of PDZK1 in ccRCC, the
correlation between PDZK1 expression levels and tumor stages
was evaluated. The results showed that PDZK1 was negatively
correlated with the tumor stage either at protein (Figures 1f,
Po0.05) or mRNA (Figures 1g, Po0.01) levels, also tumor weight
and volume (Supplementary Figures S2a and b). In addition, we
found that PDZK1 was negatively correlated with the T stage,
which reﬂected the tumor size, either at protein (Supplementary
Figure S2c, Po0.05) or mRNA (Supplementary Figure S2d,
Po0.05) levels. All these data indicate that loss of PDZK1
expression is associated with advanced tumor stage and tumor
growth. Also we found that lower PDZK1 expression correlated
with poor clinical outcome of ccRCC patients.19
PDZK1 inhibits cell proliferation, migration and invasion of ccRCC
cells
Tumor cell proliferation is a major representative indicator of
malignant phenotypes. PDZK1 was related to cell proliferation by
GO analysis using the DAVID online analysis tool, so the effects of
PDZK1 expression on ccRCC cell proliferation were investigated.
The 769-P and 786-O ccRCC cells were stably transfected with
PDZK1 expression constructs, and the overexpression of PDZK1
was conﬁrmed by western blotting (Figure 2a). Then cell viability
and colony formation were measured. The results showed that
PDZK1 overexpression in 769-P and 786-O cells led to reduced cell
proliferation (Figure 2b) and decreased colonogenicity (Figure 2c).
To further conﬁrm the results, PDZK1 was knocked down in 769-P
and 786-O cells, by stable transfection with small hairpin RNAs,
shPDZK1#1 and shPDZK1#2, respectively. Signiﬁcantly decreased
PDZK1 expression was veriﬁcated by western blotting (Figure 2d),
and the cell proliferation increased robustly in PDZK1 knockdown
cell lines (Figure 2e). These data conﬁrmed that PDZK1 expression
inhibited ccRCC cell proliferation. To explore the possible
mechanism of cell proliferation inhibition by PDZK1, we further
investigated the effects of PDZK1 on cell cycle progression using
ﬂow cytometry. As shown in Figure 2f, after depletion of PDZK1,
the percentage of 769-P cells in G0/G1 phase obviously decreased
from 66.5 to 48.1%, whereas the distribution of cells in S phase
increased from 20.7 to 37.2%. The data demonstrated that PDZK1
induced cell cycle arrest at G1/S checkpoint in ccRCC cells. Taken
together, PDZK1 expression inhibited cell growth and promoted
cell cycle arrest of ccRCC cells.
The effects of PDZK1 expression on the migration or invasion
ability of ccRCC cells were also evaluated by scratch or transwell
assays. The results showed that overexpression of PDZK1 in 769-P
and 786-O cells inhibited tumor cell migration (Figure 3a) and
invasion (Figure 3b) as compared with control cells.
To further verify the pathways associated with the pathogenesis
of ccRCC, the patients were stratiﬁed by the median levels of
PDZK1 and gene set enrichment analysis (GSEA) was performed
with TCGA ccRCC data sets; data showed that the gene signatures
of cell proliferation, cell cycle and migration were enriched in
patients with low PDZK1 expression, suggesting that PDZK1
repressed cell proliferation and migration abilities in ccRCC tissues
(Supplementary Figure S3). Taken together, our results indicate
that PDZK1 elicits a tumor-suppressive role via regulation of cell
proliferation and migration in ccRCC.
PDZK1 inhibits cell proliferation and migration of ccRCC via
targeting SHP-1
The PTPase (phosphatase) activity of SHP-1 has an important role
in cell proliferation and migration,20 so the roles of SHP-1 in
PDZK1-mediated proliferation and migration were studied in
ccRCC cells. NSC-87877, a potent inhibitor of SHP-1 phosphatase,
was used to inhibit the SHP-1 activity in 769-P cell. As shown in
Figure 4, the proliferation of 769-P cells was dose- and time-
dependently inhibited by NSC-87877, suggesting that SHP-1
activity is essential for ccRCC cell proliferation (Figures 4a and b).
To illuminate whether PDZK1 suppresses ccRCC cell proliferation
and migration by targeting SHP-1, cell proliferation and migration
assays were performed by treating the 769-P cells with NSC-87877
in the presence or absence of PDZK1. PDZK1 showed no effects on
the proliferation and migration of 769-P cells when SHP-1 activity
was inhibited by NSC-87877 (Figures 4c and d). To conﬁrm
these results, cell proliferation in 769-P cells was detected after
combined knockdown of PDZK1 and SHP-1. The results showed
that silencing PDZK1 expression signiﬁcantly promoted cell
proliferation in 769-P cells when SHP-1 existed. However,
PDZK1 had no effects on cell proliferation when SHP-1 was
knocked down (Figure 4e). Taken together, these data indicated
that PDZK1 inhibits cell proliferation and migration of ccRCC by
targeting SHP-1.
PDZK1 inhibits SHP-1 phosphorylation at Tyr536 via suppression
of SHP-1/PLCβ3 binding, leading to reduction of Akt
phosphorylation and promotion of STAT5 phosphorylation in
ccRCC cells
Lines of evidences showed that phosphatase activity of SHP-1 was
regulated by SHP-1 phosphorylation.21 To explore the regulatory
mechanism of PDZK1 on SHP-1 activity, PDZK1 expression was
changed by overexpression or knockdown in 786-O cells and
SHP-1 phosphorylation was detected. As shown in Figures 5a and
b, PDZK1 overexpression suppressed Tyr536 phosphorylation of
SHP-1 in a dose-dependent manner. Conversely, PDZK1 knock-
down increased the SHP-1 phosphorylation in 786-O cells
(Figure 5c). Consistently, the inhibitive effects of PDZK1 on
SHP-1 phosphorylation were veriﬁed in 769-P cells
(Supplementary Figure S4).
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Figure 1. PDZK1 expression is downregulated and negatively associated with advanced tumor stages of patients with ccRCC. (a, b) Scatter
plots of fold change of PDZK1 mRNA expression in ccRCC and their adjacent tissues, the data were obtained from GSE53757 (a), or from TCGA
ccRCC data set (b) (nonparametric Mann–Whitney test, Po0.001). (c) Fold change of PDZK1 mRNA expression in ccRCC compared with
normal renal tissues, the data were obtained from ﬁve independent studies published in ONCOMINE database. (d) PDZK1 protein levels in 90
human ccRCC and normal renal tissue samples were analyzed by immunohistochemistry with tissue microarray (TMA) (nonparametric Mann–
Whitney test, Po0.01). (e) Representative images of PDZK1 immunohistochemical staining in ccRCC (Right) and its adjacent tissue (Left). Scale
bars, 200 μm and 50 μm. H&E, hematoxylin and eosin. (f, g) Advanced tumor stages is associated with lower PDZK1 protein levels by a TMA
study of ccRCC patient specimens (f), or lower PDZK1 mRNA levels, with data obtained from TCGA ccRCC data sets (g). Data were analyzed by
one-way ANOVA, Po0.05.
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Figure 2. PDZK1 inhibits the proliferation of ccRCC cells. (a) Overexpression of PDZK1 in 786-O and 769-P cells was veriﬁed by immunoblotting
analysis; GAPDH was used as a loading control. (b) PDZK1 overexpression signiﬁcantly reduced cell proliferation of 786-O and 769-P cells by
CCK8 viability assays (Repeated-measures analysis of variance, Po0.05). (c) PDZK1 inhibited the colony formation of 786-O and 769-P cells.
Left panel: Representative photographs of the colonogenicity. Right panel: Quantiﬁcation of the colony formation efﬁciency. Po0.05 vs
control. (d) PDZK1 knockdown by stable transfection of shRNA in 786-O and 769-P cells, respectively, was conﬁrmed by western blotting.
(e) PDZK1 knockdown enhances cell proliferation in 786-O and 769-P cells. PDZK1 shRNA-transfected 786-O or 769-P cells were, respectively,
cultured in 96-well plates and stained with CCK8 at 72 h. Growth of 786-O and 769-P cells was assessed by measuring absorbance at 450 nm
with a spectrophotometer. Values were expressed as fold change compared with scrambled control shRNA-transfected cells (Po0.05).
(f) PDZK1 knockdown led to S phase accumulation in 769-P cells. Cell transfected with mixed two PDZK1 siRNAs and cell cycle analysis was
performed using propidium iodide DNA staining and ﬂow cytometry (t-test, Po0.01). All data were representatives of at least three
independent experiments.
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The previous report showed that SHP-1 phosphorylation was
regulated by PLCβ3.22 Therefore, we further explored the potential
roles of PLCβ3 in PDZK1-mediated suppression on SHP-1
phosphorylation. As the results shown in Figure 5d, knockdown
of PLCβ3 robustly abolished SHP-1 phosphorylation at Tyr536 in
786-O cells, and PDZK1 knockdown signiﬁcantly increased SHP-1
phosphorylation only when PLCβ3 existed. These results sug-
gested that PDZK1 inhibition of SHP-1 phosphorylation at Tyr536
required PLCβ3.
SHP-1 phosphatase activity was generally assessed by the
impact on phosphorylation of its target molecules such as STAT3,
STAT5 and Akt.20,22,23 To identify the cellular targets of SHP-1 in
renal cancer cells, the phosphorylation of STAT3，STAT5 and Akt
were explored in 769-P cells, in which PDZK1 was overexpressed
and knocked down, respectively. The results showed that PDZK1
signiﬁcantly promoted STAT5 phosphorylation, and robustly
inhibited Akt phosphorylation, with no detectable impact on
STAT3 phosphorylation (Figures 6a and b). To further conﬁrm our
initial ﬁndings, the correlation between PDZK1 mRNA levels and
activation of Akt or STAT3 signaling in ccRCC specimens was
investigated by GSEA. The results demonstrated a negative
correlation between PDZK1 level and the activation of Akt
signaling (Figure 6c), but no correlation between PDZK1 and
STAT3 activation was found in ccRCC samples (Figure 6d). The
data are in line with the results of our in vitro study. Unfortunately,
a gene set of STAT5 signaling activation was currently not
available yet, we were therefore unable to detect the correlation
of PDZK1 with STAT5 signaling activation in ccRCC specimens.
Taken together, our results indicate that PDZK1/SHP-1 inhibits
ccRCC development and progression by regulation of Akt
signaling, including possibly STAT5 signaling. These need to be
validated with further studies.
Figure 3. PDZK1 inhibits ccRCC cell migration and invasion. (a) PDZK1 overexpression inhibited cell migration by wound-healing assay. The
relative migration distance was quantiﬁed (right panel) (t-test, Po0.01). (b) PDZK1 overexpression inhibited cell invasion. The Boyden
chambers invasion assay was used. Invasive cells are represented as mean± s.d. (t-test Po0.01). All data were representatives of at least three
independent experiments.
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Studies have shown that PLCβ3 bond SHP-1 via C-terminal of
PLCβ3 to facilitate the SHP-1 phosphorylation at Tyr536.22
Meanwhile, PLCβ3 can also interact with PDZK1 via its PDZ-
binding motif at the C-terminus.24 Our results also veriﬁed these
interactions endogenously in 786-O cell (Figures 7a and b), and
deletion of the PDZ-binding motif in C-terminus of PLCβ3 (PLCβ3-
△NTQL) completely abolished its interaction with PDZK1
(Figure 7c). Interestingly, the mutation of PLCβ3-ΔNTQL
Figure 4. PDZK1 inhibits cell proliferation and migration of ccRCC via targeting SHP-1. (a) NSC-87877, a SHP-1 selective inhibitor, retarded
769-P cell proliferation in a dose-dependent manner. 769-P cells were cultured in 96-well plates and treated with different concentrations of
NSC-87877 (0 ~ 200 μM) for 72 h, respectively. Viability of the cells was assessed with CCK8 assay by measuring absorbance at 450 nm with a
spectrophotometer. Data were analyzed by one-way ANOVA (Po0.01). (b) Time course of the 769-P cells growth with NSC-87877 (100 μM)
treatment as indicated. 769-P cells were incubated with NSC-87877 at indicated time points, and cell proliferation was measured by CCK8
viability assays as described previously (Repeated-measures analysis of variance, Po0.05). (c) PDZK1 inhibited 769-P cell growth through
suppressing SHP-1 activation. 769-P and 769-P-shPDZK1 cells were cultured in 96-well plates, respectively, and treated in the presence or
absence of SHP-1 inhibitor NSC-87877 (100 μM) for 72 h, then stained with CCK8. Viability of 769-P cells was assessed by measuring absorbance
at 450 nm with a spectrophotometer. Values were represented relative to the absorbance compared with scrambled control. (d) PDZK1
inhibited 769-P cell migration through suppressing SHP-1 activation. 769-P cells transfected with siRNA control or two mixed PDZK1 siRNAs
were cultured, respectively, and treated in the presence or absence of SHP-1 PTPase inhibitor NSC-87877 (100 μM) for 24 h. The migration of
wound-healing assay was subsequently calculated (t-test, Po0.05). (e) PDZK1 inhibited 769-P cell growth dependent on SHP-1 expression.
769-P and 769-P-shPDZK1 cells were transfected with either SHP-1 siRNA#1, siRNA#2 or scramble control, respectively, and cell proliferation
was determined as described in Figure 2b. All data were representatives of three independent experiments and data are shown as mean± s.d.
*Po0.05, **Po0.01.
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signiﬁcantly enhanced the association of PLCβ3 and SHP-1
(Figure 7d); reminding that interaction between PDZK1 and
PLCβ3 retarded the association of SHP-1 and PLCβ3. To verify this
result, GST-PLCβ3-CT was used to pull down endogenous SHP-1 in
the absence or presence of different doses of His-PDZK1-PDZ1. As
shown in Figure 7e, the PDZ1 domain of PDZK1 exhibited a dose-
dependent inhibition of the association between PLCβ3 and
SHP-1. This result was further conﬁrmed in HEK293T cells by co-
transfection of Flag-PLCβ3 with different amounts of Myc-PDZK1
constructs. Immunoprecipitation of Flag-PLCβ3 followed by
western blotting analysis of SHP-1 revealed that SHP-1 co-
immunoprecipitation with PLCβ3 was concordantly reduced with
a gradual increase of PDZK1 protein level (Figure 7f). Taken
together, these results indicate that PDZK1 retards SHP-1
phosphorylation via inhibiting the association between SHP-1
and PLCβ3.
PDZK1 inhibits the ccRCC cell proliferation in vivo by blocking
SHP-1 phosphorylation
To examine the roles of PDZK1 in vivo, a model of xenograft tumor
was generated through subcutaneously injecting PDZK1 over-
expressed or control ccRCC cells into nude mice. Overexpression
of PDZK1 suppressed the growth of ccRCC xenografts within
16 days (Figure 8a). Accordingly, the weight and volume of tumors
were signiﬁcantly decreased in PDZK1 overexpressed group as
compared with the control (Figures 8b–d). Immunohistochemical
staining analysis showed that PDZK1 overexpression decreased
the Tyr536 phosphorylation of SHP-1, and reduced the expression
of Ki67, the cell proliferation marker (Figure 8e). These results
suggest that PDZK1 suppresses tumor cell proliferation by
inhibiting the phosphorylation of SHP-1 in xenograft tumor of
ccRCC cells.
To further explore the correlation of PDZK1 and SHP-1
phosphorylation in ccRCC tissues, the expression levels of PDZK1
and phosphorylated SHP-1 were examined with western blotting.
As compared with the paracancerous tissues, PDZK1 protein level
was markedly decreased in ccRCC tissues. Accordingly, SHP-1
phosphorylation levels were signiﬁcantly increased in ccRCC
tissues (Figure 9a).
To delineate relevance of SHP-1 activation in ccRCC develop-
ment and progression, gene signatures in response to SHP-1
activation were analyzed in TCGA database of ccRCC patients.
Data showed that the gene signatures speciﬁc to SHP-1 activation
were enriched in ccRCC patients with cancer or poor prognosis
(Figure 9b and c), suggesting that SHP-1 activation was positively
associated with ccRCC development and progression. To further
verify whether loss of PDZK1 expression is associated with SHP-1
activation, GSEA was also used to test the enrichment value of
SHP-1 activation related with PDZK1 mRNA levels. Results showed
that gene signatures of SHP-1 activation were positively enriched
in PDZK1 low expression group (false discovery rate = 0.001)
(Figure 9d). These ﬁndings provide ﬁrst lines of evidences that
PDZK1 levels are negatively correlated with SHP-1 activation,
suggesting that loss of PDZK1 in ccRCC patients may contribute to
the tumorigenesis and progression of ccRCC via activation of
SHP-1 (Figure 9e).
Figure 5. PDZK1 blocks SHP-1 phosphorylation at Tyr536. (a) PDZK1 overexpression reduced SHP-1 phosphorylation. After 24 h of transfection
with constructs of myc-PDZK1 or control vectors in 786-O cells, the endogenous SHP-1 phosphorylation at Tyr536 was detected by
immunoblotting. (b) PDZK1 decreased the SHP-1 phosphorylation at Tyr536 in a dose-dependent manner. After 24 h transfection with
increased amounts of constructs of myc-PDZK1 or control vectors in 786-O cells, the SHP-1 phosphorylation at Tyr536 and total SHP-1 were
detected by immunoblotting. (c) Knockdown of PDZK1 expression increased SHP-1 phosphorylation in 786-O cells. 786-O cells transfected
with either PDZK1 siRNA or scramble control, and the SHP-1 phosphorylation at Tyr536 was determined. Total expression levels of SHP-1 and
GAPDH were shown as loading controls. (d) Inhibition of SHP-1 phosphorylation by PDZK1 required PLCβ3 expression. 786-O sicontrol and
786-O siPDZK1 cells were transfected with either PLCβ3 siRNA or scramble control respectively, and the SHP-1 phosphorylation at Tyr536 in
786-O cells was determined. Total expression levels of SHP-1 and GAPDH were shown as loading controls. All data were representative of
three independent experiments.
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DISCUSSION
Aberrant PDZK1 expression has been observed in several kinds of
cancers, and it is involved in tumor cell signaling via its PDZ
domain mediated protein-protein interaction.25,26 However, the
role and relevance of PDZK1 in renal cancer are largely unknown.
Here, we identiﬁed PDZK1 as a downregulated gene in ccRCC
through the analysis of mRNA expression proﬁle obtained from
the GEO series GSE53757, and revealed PDZK1 as a cell
proliferation-related PDZ protein by functional clustering analysis.
We provided the evidences that PDZK1 has tumor-suppressive
roles in ccRCC. PDZK1 was signiﬁcantly decreased in ccRCC at
mRNA and protein levels. Loss of PDZK1 was in positive
correlation with advanced tumor stage and larger tumor size of
ccRCC (Figure 1 and Supplementary Figure S2). Studies in ccRCC
cells revealed that PDZK1 overexpression inhibited cell prolifera-
tion, migration and invasion (Figure 2 and Figure 3), whereas
PDZK1 knockdown enhanced cell proliferation (Figures 2d and e).
Furthermore, PDZK1 overexpression inhibited tumor growth of
xenografts derived from ccRCC cells in nude mice (Figure 8). These
ﬁndings support that PDZK1 plays a crucial role in renal
carcinogenesis and progression.
It is well known that PDZK1 can interact with multiple proteins
and regulate downstream cell signaling.24,27 Here we showed that
PDZK1 interacts with PLCβ3 and affects SHP-1 activation. SHP-1, a
member of protein tyrosine phosphatases (PTPs), is previously
reported to be largely expressed in the hematopoietic cells and
has a role as a tumor suppressor.28 In solid tumors, SHP-1 is also
broadly expressed, however, its expression has been found to
correlate with worse survival of breast cancer, glioma and prostate
cancer.20,29,30 It indicates that SHP-1 had tumor-promoting activity
in solid tumors. In this study, we found that suppression of SHP-1
activation or expression by its selective inhibitor NSC-87877 or
siRNA retarded ccRCC cell proliferation and migration. Also we
showed that PDZK1 suppressed cell proliferation, migration of
ccRCC cells by targeting SHP-1 (Figure 4). To explore the molecular
mechanism by which SHP-1 regulates the renal cancer cells, the
Figure 6. PDZK1/SHP-1 regulates Akt and STAT5 signaling in ccRCC cells. (a) PDZK1 overexpression retarded Akt phosphorylation, and
promoted STAT5 phosphorylation. After 24 h transfection with constructs of myc-PDZK1 or control vectors in 769-P cells, the phosphorylation
of Akt, STAT5, STAT3 and SHP-1 was detected by immunoblotting. (b) Knockdown of PDZK1 expression increased Akt phosphorylation and
decreased STAT5 phosphorylation in 769-P cells. 769-P cells were transfected with either two mixed PDZK1 siRNAs or scramble control for
48 h, the phosphorylation of Akt, STAT5, STAT3 and SHP-1 was detected by immunoblotting. Total protein contents of Akt, STAT5, STAT3 and
SHP-1 were shown as loading controls. (c, d) Enrichment plots of gene expression signatures for Akt (c), and STAT3 (d) pathway activation
according to PDZK1 mRNA expression levels by GSEA of TCGA ccRCC database. The ccRCC samples were divided into high and low PDZK1
expression groups based on the median values of PDZK1 RNA-seq quantiﬁcation results. The results showed that PDZK1 level had signiﬁcant
negative correlation with Akt activation (FDR= 0.111), but no correlation with STAT3 activation (FDR= 0.768) in ccRCC samples.
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activation or phosphorylation of potential target proteins of
SHP-1, such as Akt, STAT3 and STAT5, and the levels of total
tyrosine phosphorylation were detected. Our results showed that
no signiﬁcant change was found in either levels of total tyrosine
phosphorylation or STAT3 phosphorylation in ccRCC cells with
SHP-1 or PDZK1 knockdown, as well as in the cell pretreated with
NSC-87877 (Supplementary Figure S5). However, with either
overexpression or knockdown in 769-P cells, PDZK1 was demon-
strated to inhibit Akt phosphorylation, and promote STAT5
phosphorylation. Rodríguez-Ubreva FJ et al.20 previously reported
that SHP-1 promoted Akt Ser473 phosphorylation via inhibiting
Tyr phosphorylation of p110 catalytic subunit of PI3K, our results
Figure 7. PDZK1 impairs the association between SHP-1 and PLCβ3. (a) PDZK1 associated with PLCβ3 in 786-O cells. The cell lysates of 786-O cells
were immunopreciptated with rabbit IgG or anti-PLCβ3 monoclonal antibodies, and then the co-immunopreciptation of PDZK1 with PLCβ3 was
determined by immunoblotting with anti-PDZK1 antibodies. (b) PLCβ3 associated with SHP-1 in 786-O cells. The cell lysates of
786-O cells were immunopreciptated with rabbit IgG or anti-PLCβ3 monoclonal antibodies, and then the SHP-1 co-immunopreciptation with
PLCβ3 was determined by immunoblotting with anti-SHP-1 antibodies. (c) The carboxyl terminal of PLCβ3 was essential for PLCβ3 binding to
PDZK1. COS7 cells were transfected with PLCβ3 wild-type (Flag-PLCβ3-WT) or its deletion mutant lacking PDZ-binding motif (Flag-PLCβ3-ΔNTQL).
Cell lysates were pulled down with GST-PDZ1 domain of PDZK1 and GST fusion proteins. The pulled down PLCβ3 was detected by western
blotting with anti-Flag antibody (top panel). (d) The mutation of PDZ-binding motif deletion in PLCβ3 increased the association of PLCβ3 and
SHP-1. 786-O cells were transfected with constructs of Flag-PLCβ3-WT or Flag-PLCβ3-ΔNTQL. Cells were solubilized and incubated with anti-Flag
antibody coupled to beads. Co-immunoprecipitation of SHP-1 with Flag-PLCβ3 was detected by western blotting with anti-SHP-1 antibodies. (e)
The interaction of SHP-1 and PLCβ3 was inhibited by PDZ1 domain of PDZK1 in a dose-dependent manner. Endogenous SHP-1 of ACHN cells was
pulled down with GST fusion proteins of wild-type PLCβ3 in the presence of different amount of puriﬁed His-PDZK1-PDZ1 protein. SHP-1 in the
pulled down complexes was detected by western blotting. (f) Full-length PDZK1 inhibited the interaction of SHP-1 and PLCβ3 in a dose-
dependent manner in cells. HEK293T cells were transfected with Flag-PLCβ3 plasmid (1 μg) and increased amount of Myc-PDZK1 plasmid (0, 0.5,
1 μg). After 24 h transfection, cells lysates were immunoprecipitated with anti-FLAG antibodies. Co-immunoprecipitations of SHP-1 and PDZK1
were analyzed by western blotting. All data were representatives of three independent experiments.
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suggested that PDZK1 retarded Akt phosphorylation possibly via
regulating SHP-1-PI3K-Akt pathway. This negative correlation
between PDZK1 and Akt activation was also conﬁrmed in the result
analyzed with clinical ccRCC specimens using GSEA method
(Figure 6c).Take together, these data indicate that PDZK1 or SHP-1
is unable to alter general tyrosine phosphorylation; however, SHP-1
could selectively dephosphorylate some speciﬁc target proteins as
Akt or STAT5, and then inhibit ccRCC development and progression.
These results need to be validated with further studies.
SHP-1 is composed of two tandem domains of N-SH2 and C-SH2,
followed by the catalytic domain of PTP and C-terminal tail, which
contains key tyrosine phosphorylation sites in the regulation of
SHP-1 activity.21 N-SH2 is located closely to the PTP catalytic domain
of SHP-1, which restricts accession of PTP catalytic domain and
substrate of phosphatase. When SHP-1 Tyr536 phosphorylated, the
PTP catalytic domain was separated from N-SH2 to become
accessible for its substrates (Figure 9e). This is conﬁrmed by that
reduced SHP-1 phosphorylation at Tyr536 results in a drastic
reduction of SHP-1 phosphatase activity.22
Recent reports reveal that PLCβ3 acts as a scaffold to associate
with SHP-1 and recruits tyrosine kinase to phosphorylate SHP-1 by
forming a macromolecular complex.22 In the current study, we
showed that PLCβ3 knockdown inhibited SHP-1 phosphorylation
in ccRCC cells (Figure 5d), indicating that PLCβ3 is required for the
SHP-1 phosphorylation at Tyr536. Our study also showed that
PDZK1 dose-dependently inhibited SHP-1 phosphorylation
through blocking the association between SHP-1 and PLCβ3
(Figures 5a and b, Figures 7e and f). Taken together, our data
Figure 8. PDZK1 inhibits tumor growth and SHP-1 phosphorylation in xenograft tumors. (a) The growth curve of subcutaneous xenograft
tumor from ACHN cells in nude mice. ACHN or ACHN-PDZK1 cells were subcutaneously injected into nude mice. Tumor size was measured
every 2 days. Values were presented as the mean± s.d. of 12 mice in each group. (Repeated-measures analysis of variance, Po0.01) (b) The
dissected tumors from the xenografted mice inoculated with ACHN-PDZK1 or control cells. Mice were sacriﬁced at a minimum of 16 days after
transplantation. (c, d) Mean tumor weights and tumor volumes of ACHN-PDZK1 group were signiﬁcantly smaller than those in the ACHN
control group. Xenograft tumors were dissected, and their weight and volumes were measured and comparative analyzed between PDZK1
overexpression group and control group of nude mice. (e) IHC staining of PDZK1, pSHP-1 and Ki67 of the PDZK1 overexpressed or control
xenografts were shown. Scale bar represented 20 μm, respectively.
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suggest that PDZK1 inhibits SHP-1 phosphorylation by suppres-
sion of the association between SHP-1 and PLCβ3.
As a member of PLCβ family, PLCβ3 generally has its function
via the phospholipase activity-dependent pathway.31 Recently,
studies have shown that PLCβ3 can also act as a scaffold to
recruit some tyrosine kinases via its non-catalytic C-terminal
domain to facilitate SHP-1 phosphorylation.22 In this study,
we found that PDZK1 retarded SHP-1 phosphorylation via
the inhibition of the association between SHP-1 and PLCβ3.
Interestingly, PLCβ3 is found to be upregulated and correlated
with poor prognosis in renal cancer patients (data not shown).
These results are consistent with the ﬁnding that upregulated
PLCβ3 increased the phosphorylation of SHP-1 in ccRCC
cells, indicating that PLCβ3 may have a tumor-promoting role in
Figure 9. SHP-1 PTPase activity is upregulated in ccRCC, positively correlated with poor prognosis and negatively correlated with PDZK1
expression levels in ccRCC patients. (a) Negative correlation between expression levels of PDZK1 and SHP-1 phosphorylation. The expression
levels of PDZK1 and phosphorylated SHP-1 of ccRCC specimens and their adjacent tissues were analyzed by western blotting, and total
expression levels of SHP-1 and GAPDH were shown as loading controls. (b–d) SHP-1 is activated in ccRCC, and its activity is positively
correlated with poor prognosis and low PDZK1 expression of ccRCC. The gene signatures of SHP-1 activation was signiﬁcantly enriched in
ccRCC, poor prognosis and low PDZK1 expression groups as compared with normal, good prognosis and high PDZK1 expression groups,
respectively. (e) Schematic illustration of the mechanism of the enhancement of SHP-1 phosphorylation owing to loss of PDZK1 and its
association with PLCβ3 in ccRCC.
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renal cancer. However, this hypothesis need to be further
explored.
In this study, we found that PDZK1 was signiﬁcantly down-
regulated in ccRCC, and loss of PDZK1 was correlated with higher
TNM staging in TCGA database. Similar results were obtained by a
tissue microarray study of ccRCC patient specimens. Importantly,
loss of PDZK1 was remarkably correlated with poor prognosis of
ccRCC patients.
As we know, VHL-HIF-1α pathway has a critical role in ccRCC. To
investigate whether VHL-HIF-1α pathway is involved in PDZK1-
mediated inhibition on the development and progression of ccRCC,
cell lysates of 769-P and 786-O were immunoblotted, respectively,
to detect HIF-1α expression, and no detectable expression of HIF-1α
was observed in either 769-P and 786-O cells (Supplementary
Figure S6a). GSEA results show that PDZK1 expression has no
correlation with gene signatures of HIF-1/2α signaling activation in
clinical ccRCC specimens (Supplementary Figure S6b and c),
indicating that PDZK1 inhibits the development and progression
of ccRCC probably independent of VHL-HIF pathway.
In conclusion, PDZK1 is identiﬁed as a novel tumor suppressor
in ccRCC and has been demonstrated its inhibition on prolifera-
tion, migration and invasion by targeting SHP-1. Loss of PDZK1
expression is correlated with SHP-1 activation and poor clinical
outcomes in ccRCC. Taken together, our ﬁndings provide novel
clues for understanding of ccRCC carcinogenesis.
MATERIALS AND METHODS
Reagents and antibodies
NSC-87877 (565851), a SHP-1 selective inhibitor, was purchased from
Calbiochem (Millipore, Billerica, MA, USA). The following antibodies were
purchased: anti-His antibody from MBL (Nagoya, Japan), anti-Myc antibody
from Applygen (Beijing, China), anti-PDZK1 antibody and anti-phosphor-
SHP-1 (Tyr536) antibody from Abcam (Cambridge, UK), anti-PLCβ3 and anti-
SHP-1 from Santa Cruz (Dallas, TX, USA), anti-FLAG M2 antibody and FLAG
M2-agarose from Sigma (St Louis, MO, USA), anti-STAT5, anti-phosphor-
STAT5 (Tyr694), anti-STAT3, anti-phosphor-STAT3 (Tyr705), anti-phosphor-
Akt (Ser473) and anti-Akt from CST (Danvers, MA, USA), HRP-conjugated
secondary antibodies and anti-GAPDH from ZSGB-BIO (Beijing, China).
Data sets collection and ccRCC patient samples
Totally six ccRCC tissues and matched adjacent renal tissues were collected
from the First Hospital of Shanxi Medical University of Taiyuan during 2010.
Patients who signed the informed consents were included. This study has
been approved by Ethics Committee of Shanxi Medical University. The tissue
microarrays of ccRCC, containing biopsies from 90 ccRCC and its adjacent renal
tissues, were purchased from Shanghai Outdo Biotech (Shanghai, China).
The GEO data set GSE53757, which consisted of 72 paired renal cancer
and adjacent renal tissues, was used for the differential expression genes
screening and GO analyses. TCGA ccRCC RNA-Seq and matching clinical
data were collected from Synapse website (http://synapse.org;
syn1461159). RNA-Seq analysis was performed with the TCGA data of
531 ccRCC and 72 adjacent renal tissues.
GEO2R and GO analyses
GEO2R analyzer, a software tool for analyzing the data in GEO database, was
used to analyze the public available GSE53757 data.32 A total of 144 samples
were divided into two groups: 72 ccRCC tissues and 72 matched adjacent
renal tissues. The cutoff criteria for screening differentially-expressed mRNAs
was: Po0.05 and the fold change of expression levels42.0. To explore the
functional annotation enrichment of genes, the GO analyses were performed
with DAVID tools (http://david.abcc.ncifcrf.gov/).
Gene set enrichment analysis
GSEA was carried out as previously33 to assess user-deﬁned gene sets
described as follows: SHP-1 activation gene set was deﬁned as genes
upregulated at least 1.5-fold changes associated with stimulation of SHP-1
PTPase activities (GSE42922). Akt signaling gene set (HALLMARK_PI3-
K_Akt_SIGNALING) and STAT3 signaling gene set (AZARE_STAT3_TARGETS)
were obtained from Molecular Signatures Database from the Broad
Institute (http://software.broadinstitute.org/gsea/msigdb). Tests were per-
formed by using the default settings, and permutations number was set at
1000. False discovery rate o0.25 was considered statistically signiﬁcant.
Immunohistochemistry
The samples used for immunohistochemistry analysis include tissue
microarray of human tissues, and mice tumor xenograft. Immunohistochem-
istry was performed as described previously.34 Primary antibodies were
incubated at the optimal conditions (PDZK1, 1:100, Abcam; pSHP-1, 1:100,
Abcam; Ki67, 1:100, Santa Cruz). Omitting primary antibodies were used as
negative control. IPP software was used to analyze optical densitometry.
Cell culture and transfection
COS7 and HEK293 cells were purchased from European Collection of
Animal Cell Culture (ECACC, Porton Down, Salisbury, UK). The human renal
carcinoma cell lines 769-P, 786-O and ACHN were obtained from American
Type Culture Collection (ATCC, Manassas, VA, USA). Cells were grown in
DMEM medium (COS7 and HEK293) or RPMI-1640 medium (769-P, 786-O
and ACHN) containing 10% fetal bovine serum (complete medium) and 1%
streptomycin/ penicillin, at 37 °C and 5% CO2. All cell culture reagents were
provided by HyClone (Logan, UT, USA). Cells were transfected by using
Lipofecamine 2000 (Invitrogen, Carlsbad, CA, USA). For cell stable
transfection, PDZK1 plasmid and control vector were transfected into
786-O, 769-P or ACHN cells and screened with G418 (800 mg/ml; Amresco,
Solon, OH, USA). For stable knockdown transfection, shPDZK1 plasmid and
shControl vector were transfected into 786-O or 769-P cells. Stably
transfected cells were selected by using 300 ng/ml puromycin (Sigma).
Plasmid constructions and RNA interference
The constructs encoding Myc-PDZK1, Flag-PLCβ3, GST-PLCβ3-CT, GST-
PDZK1-PDZ1 and His-PDZK1-PDZ1 were generously supplied by Dr Randy
Hall (Emory University, GA, USA). The PLCβ3-CT is comprised of the
C-Terminal 50 amino acids of human PLCβ3. The construct of C-terminal
PDZ-binding motif (NTQL)-deleted PLCβ3 was derived from Flag-PLCβ3 by
PCR and veriﬁed by bidirectional sequencing.
Small interfering RNA (siRNA) duplexes were synthesized by Sigma-
Aldrich and the siRNA sequences were as below:
PDZK1 siRNA-#1, sense 5′-CAAAGAAACUGACAAGCGUdTdT-3′ and anti-
sense 5′-ACGCUUGUCAGUUUCUUUGdTdT-3′; PDZK1 siRNA-#2, sense
5′-GUCAAAUCAUCAAGGACAUdTdT-3′ and anti-sense 5′-AUGUCCUUGAU
GAUUUGACdTdT-3′; SHP-1 siRNA-#1, sense 5′-GCAUGACACAACCGAAUA
Ctt-3′ and anti-sense 5′-GUAUUCGGUUGUGUCAUGCtc-3′; SHP-1 siRNA-#2,
sense 5′-GGUGACCCAUAUUCGGAUCtt-3′ and anti-sense 5′-GAUCCGAAUA
UGGGUCACCtg-3′. The control siRNA (sc-37007) and siRNA against PLCβ3
(sc-36272) were obtained from Santa Cruz Biotechnology. The plasmids of
shPDZK1#1 and shPDZK1#2 which are employed to stable knockdown of
PDZK1 were kindly offered by Dr Michael R Beard.27
Cell proliferation measurement
Cells were seeded in 96-well plates (3000 cells per well). Plates were then
incubated for 24-72 h, and viable cells were analyzed with Cell Counting
Kit-8 (Dojindo, Kumamoto, Japan) by using a Enspire, microplate reader
(Perkin Elmer, Waltham, MA, USA) at 450 nm.
Colony formation assay
Cells were digested into a single cell suspension and seeded in six-well
plates (300 cells per well). After incubation for 14 days, cells were stained
with crystal violet, and then the colonies (450 cells) were counted.
Cell cycle analysis
Cell cycles were examined by ﬂow cytometry. After ﬁxing for 30 min in cold
ethanol, cells were then incubated with propidium iodide for 30 min
before ﬂow cytometry (BD Biosciences, San Jose, CA, USA) analysis.
Cell migration and invasion assay
Cell migration was performed with in vitro scratch assay as previously
described.35 The invasion assay was determined using modiﬁed Boyden
chambers coated with Matrigel in 24-well plate (Becton-Dickinson
Biosciences, Bedford, MA, USA).
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In vivo xenograft formation assay
The study was approved by the Capital Medical University Animal Care and
Use Committee. ACHN cells stable transfected with PDZK1 or vector
control were subcutaneously implanted into the dorsal ﬂank in each of
Balb/c nude mice (4–5 weeks) (1 × 105 cells in 0.1 ml PBS). Each group
included 12 mice. The mice were monitored every two days for the growth
of tumors, and they were killed after 5 weeks. The tumor xenografts were
dissected and weighted after the deaths of the mice. Tumor volumes were
estimated according to the equation: volume=width (mm)×width
(mm)× length (mm)/2.
GST pull down, co-immunoprecipitation and western blotting
Puriﬁcation of GST- or His-tagged proteins and GST pull down assay, lysis
of cells and tumor samples, co-immunoprecipitation and immunoblotting
were carried out as described previously.36
Statistical analysis
The statistics software of the SPSS (SPSS Inc, Chicago, IL, USA), or Graphpad
Prism 5.0 (Graphpad Software, Inc., La Jolla, CA, USA) were used in this
study. P-valueo0.05 was considered statistically signiﬁcant.
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